US Patent Issued to Novartis, The Trustees of the University of Pennsylvania on April 21 for "Treatment of cancer using humanized anti-CD19 chimeric antigen receptor" (Massachusetts, Pennsylvania Inventors)

ALEXANDRIA, Va., April 21 -- United States Patent no. 12,606,636, issued on April 21, was assigned to Novartis AG (Basel, Switzerland) and The Trustees of the University of Pennsylvania (Philadelphia).

"Treatment of cancer using humanized anti-CD19 chimeric antigen receptor" was invented by Jennifer Brogdon (Sudbury, Mass.), Carl H. June (Merion Station, Pa.), Andreas Loew (Boston), Marcela Maus (Lexington, Mass.) and John Scholler (Narberth, Pa.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The invention provides compositions and methods for treating diseases associated with expression of CD19. The invention also relates to chimeric antigen receptor (CAR) specific to CD19, vectors encoding the same, and re...